TACSTD2 and urinary bladder cancer: For instance, NECTIN-4, the TAA of Enfortumab-vedotin that is approved for bladder cancer, displayed higher expression in some non-transformed tissues like esophagus epithelium (CESC-normal) than in the tumor; or Trop2 the TAA of Sacituzumab-govitecan that is approved in breast cancer (BRCA), also showed high expression levels in head and neck epithelium (HNSC-normal).